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Use of subcutaneous anSbiotics to treat pseudomonas infection in 
an adult CF centre 
J. Cr awley, M.J. Ledson, M.J. Walshaw 
RegionaI AduIt CF Unit, The Cardiottu~racic Centre, Liverpool, UK 
In t  reduction. When totally implant able venous access devices become thr ombosed 
or infected in CF patients with poor peripheral venous access, it may be impossible 
to administer the IV antibiotics required when the patient is ill. Under these 
circumstances other access routes must be sought, including the use of a 
subcutaneous infusion where the antibiotic has a mode of action which is optimized 
by a steady serum level (such as the beta lactams). Met  openem and ceftazidime are 
suitable for subcutaneous infusion as they have a neutral pH and suitable osmolality 
can be achieved at high concentrations. 
Method.  To test this further, we administered these antibiotics via a continuous 
subcutaneous illfu sion in CF patients whose venous access was impossible, during 
chest exacerbations due to Pseudomotw~s aeruginosa. Clinical parameters of 
improvement mad any side effects were noted. 
Results. Patients were treated by continuous ubcutaneous infusion with either 
meropenem (2 courses of 10 and 14 days duration, 4g per 24 hours) or ceftazidime 
(2 courses of 11 and 14 days duration, 6g per 24 hours), accompanied by nebulised 
TOBI ® in 3 cases, ha every case cl inical improvement was noted (start mean 
FEV1% predicted 45 [range 38 to 54]; f inish mean FEV1% predicted 54 [range 45 
to 61]). Al l  infusions were tolerated wel l  with only one infusion set requiring re 
siting. 
Conclusions. This study has sbown that where appropriate, antibiotics can be 
administered by continuous subcutaneous infusion in CF individuals.  We 
recommend this approach to other clinicians with CF patients with problematic 
venous access. Further work needs to be done to establish the optimum doses 
required for best cl inical effect. 
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Chronic pseudomonas aeruginosa infection can be postponed by a 
treatment based on earlier sputum detecSon 
A. Munck I, P. Mar iani  Kur kdj ian 2, M. Get ardin 1, C. Alberti s, B. Delaisi  1,E. B ingen 2
ICF Centre; 2Microbiology, sClinicaI epidemiology, Hospital Robert Debt~, Paris, 
Fra~h2e 
Since 1990, we  prescribe an IV antibiotic ombination on initial PA and a cobort 
isolation policy. By 1996, we lowered sputum PA level detection (ld) to allow an 
earlier treatment on initial and further colonizations. A im:  to compare the impact of 
a treatment based on low PA ld  on the onset of PA chronic infection (CI). Pat ients:  
included at their initial PA. Gr A:PA ld > 1@ CFU/ml (04/90 04/95) (n 17), Gr 
B:PA ld > 1@ CFU/ml (04/96 04/01) (n 30). Both Gr received beta lactamin / 
tobramycin and over 2 m INH colistin, were sampled at least quarterly and treated 
for PA intermittent colonization. Methods:  PA Id:I@CFU/ml Gr A, 1@ ha Gr B. PA 
CI:3 positive cultures (>105 CFU/ml) during 6 m or > 2 PA serum antibodies (cross 
immtmcelect r opbor esis ).Statistical mmlysis: chi square test (qualitative variables), 
Wilcoxon test (quantitative variables) mad log rank test (Kaplan Meier  curve). 
Results: at inclusion there were no differences for median age (A:3 y ; B:2 y), 508 
frequency, delay in initiation and duration of the first IV cure, PA eradication rate 
(A:76%; B:ICO%), median fol low up duration (A:5.2 y; B:4.7 y). Init ia l  
exacerbation symptoms were more frequent ha Gr A (76% vs 30% p < 0.001). 
Median PA CFU/ml was higher in Gr A (10 ~ vs 10 a, p~).CO2). CI developed ha 8/17 
Gr A (47%) vs 1/30 Gr B (3%) (p< 0.CO1). When calculated as a Kaplan Meier  
estimate, 50% from Gr A become CI after 7 y vs 10% from Gr B (p<10s). Even those 
of Gr B who initial ly had > 1@ CFU/ml (14/30) prevented their CI r isk (1/14) taking 
advantage of intensive treatment. Conclusion: Lowering sputum PA detection 
associated to early treatment may delay the risk of CI. We encourage CF centres to 
initiate or pursue this bacteriological pproach. 
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A review of outpatient segregation policies across specialist CF units 
in the UK 
P. Dyce, C. Cowperthwaite, H. Mil ler, C. McManus, K. Moban, M.J. Ledson, M.J. 
Walshaw 
Regional Adult CF Unit, The Cardiotlu~racic Centre, Liverpool UK 
Aims:  Cross infection is becoming an i creasingly important issue in CF, and the 
UK CF Trust recently updated its guidelines for patient segregation t  l imit the 
spread of transmissible organisms between patients. Although many units separate 
inpatients to prevent cross infection, we had the impression that this might not 
extend to outpatient services. We therefore undertook a survey of outpatient 
segregation policies in CF units in the UK. 
Methods:  26/44 CF centres (10 paediatric, 14 adults and 2 both) were surveyed 
using a standard questionnaire. 
Resulrs: 24 traits (92%) had an operational policy for patient segregation for their 
outpatient services. Al l  traits had separate clinics for those infected with B cepacia, 
with 23 traits (96%) taking note of genomovar status. 21 traits (81%) segregated 
MRSA patients from the remainder. A further 21 traits (81%) segregated P 
aeruginosa patients from the remainder (10 [80%] paediatric units and 11 [69%] 
adult units). However, only 11 units (48%, 3 paediatric) segregated their patients 
infected with P aeruginosa based on strain type, thereby preventing cr ossinfection 
(superinfection) with transmissible strains. 14 units (54%) have plans to change 
their policy for outpatient segregation i cluding increasing the number of clinics, 
typing different P aeruginosa strains, mad further segregation of MRSA and B 
cepacia. 
Conclusions: It is apparent from this survey that despite xpert guidance from the 
UK CF Trust, segregation practices to prevent cross infection with transmissible 
organisms in CF across the UK are variable, mad in some units current policies wi l l  
have a deleterious effect by encouraging superinfection. Further work is needed to 
ensure that "best practice" is standard flit oughout he UK. 
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AntibioSc Synergy Against Pseudomonas Aeruginosa in patients 
with Cystic Fibrosis 
A. Bisiklis 1, M. Fot oulaki 9, P. Tsioutsias 1,St. Alexiou Daniel  1, S. Nousia Arvanit akis 2 
iDepartrnent of Microbiology, AHEPA University Hospital, School of Medic#le, 
Thessaloniki, Greece, 2Fourth Pediatric Department, Aristotle University of 
Thessaloniki, Greece 
OBJECTIVE: The purpose of our study was to evaluate the ffectiveness of 
different antibiotic ombinations against Pseudomonas aeruginosa strains applying 
the E4est method. 
MATERIALS AND METHODS:  Twenty Pseudomonas aeruginosa strains which 
were isolated from sputum cultures obtained from cystic fibrosis patients were 
studied. The identification was performed by API 20NE. We evaluated the 
fol lowing antibiotic combinations: amikacin+meropenem, a ikacin+ceftazidime 
and amikacin+piperaci l l in/tazobactam. A l l  strains revealed homogeneous or 
intermediate r sistance to amikacin. The min imum hahibitory concentrations of 
antibiotics were determined by the E test method on M611er Hinton agar. The 
evaluation of antibiotic synergy was based on fractional hahibitory concentration 
@i t ) .  
RESULTS: 
Cumulative Unintereated 
Combination Synerg¢ activity activity Antagonism 
Amikacin + Meropenem 21% 43% 28% 8% 
Amikacin + Ce ftmddime 7% 28% 50% 15% 
Amikacin + Piperacilfinffazobactam 7% 36% 36% 21% 
CONCLUSIONS: Amikacin + Meropenem combination gave the best synergy and 
cumulative activity and the lowest antagonism. This f inding supports the choice of 
the combination of these two antibiotics in empirical chemotherapy in cystic 
fibrosis patients. 
